Danvatirsen

Phase 2RNA therapy

AstraZeneca

Danvatirsen is one of 116 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

CancerActive, not recruiting

AML/MDSRecruiting

Phase IIActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

CancerPhase 1

Active, not recruiting

AML/MDSPhase 1

Recruiting

Phase IIPhase 2

Active, not recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Avastin

Gemzar

85 3

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

2 4

Danvatirsen

AstraZeneca

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1Recruiting

AML/MDS

NCT05986240

Clinical

Trials by Indication[1]

Pembrolizumab1 trial

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Terminated·FFlamingo Therapeutics NV·Phase 2·NCT05814666·69 enrolled

Cancer1 trial

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT03819465·175 enrolled

Non-Small Cell Lung Cancer1 trial

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02983578·39 enrolled

Phase II1 trial

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03334617·528 enrolled

AML/MDS1 trial

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

Recruiting·MMontefiore Medical Center·Phase 1·NCT05986240·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Danvatirsen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Danvatirsen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Danvatirsen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Danvatirsen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Pembrolizumab1 trial

Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Phase II1 trial

AML/MDS1 trial

References

Drug Info

Quick Facts

Related News